L E Fein
Overview
Explore the profile of L E Fein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
216
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Geyer Jr C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, et al.
Ann Oncol
. 2022 Oct;
33(12):1250-1268.
PMID: 36228963
Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic...
2.
Seidman A, Brufsky A, Ansari R, Hart L, Stein R, Schwartzberg L, et al.
Ann Oncol
. 2010 Nov;
22(5):1094-1101.
PMID: 21084429
Background: Safety and efficacy of gemcitabine plus docetaxel (GD) and capecitabine plus docetaxel (CD) were compared in patients with metastatic breast cancer, where the alternate crossover monotherapy (GD→C or CD→G)...
3.
Kaufmann M, Bajetta E, Dirix L, Fein L, Jones S, Zilembo N, et al.
Clin Breast Cancer
. 2002 Apr;
1 Suppl 1:S15-8.
PMID: 11970744
We compared the efficacy and safety of the oral aromatase inactivator exemestane (EXE) with megestrol acetate (MA) in women with metastatic breast cancer. This phase III randomized, double-blind, multicenter study...
4.
Kaufmann M, Bajetta E, Dirix L, Fein L, Jones S, Cervek J, et al.
Eur J Cancer
. 2000 Nov;
36 Suppl 4:S86-7.
PMID: 11056333
Exemestane is an aromatase inactivator. 769 Postmenopausal women with advanced breast cancer who had failed on tamoxifen were randomised to exemestane or megoestrol acetate in this double-blind trial. Objective response...
5.
Kaufmann M, Bajetta E, Dirix L, Fein L, Jones S, Zilembo N, et al.
J Clin Oncol
. 2000 Mar;
18(7):1399-411.
PMID: 10735887
Purpose: This phase III, double-blind, randomized, multicenter study evaluated the efficacy, pharmacodynamics, and safety of the oral aromatase inactivator exemestane (EXE) versus megestrol acetate (MA) in postmenopausal women with progressive...